Research Paper Volume 14, Issue 12 pp 5271—5291

Figure 5. Prognostic value and external validation of DMS signature. (A) Differences in DMS score between hepatitis B virus positive and negative group in TCGA-LIHC cohort. (B) Differences in DMS score between hepatitis C virus positive and negative group in TCGA-LIHC cohort. (C) Differences in DMS score between ALT high and low group in GSE14520 cohort. (D) The MaxStat R package identified the optimal cut-off point to dichotomize DMS. (E) Kaplan-Meier curves showing the survival difference between the low and high DMS groups in TCGA-LIHC cohort. (F) External validation the value of DMS in predicting patient prognosis in GSE14520 cohort. (G) Kaplan-Meier curves showing the recurrence-free survival difference between the low and high DMS groups in GSE14520 cohort. (H, I) The waterfall plot showing the differences of TMB landscape between low and high DMS groups in TCGA-LIHC cohort. (H) High DMS group. (I) Low DMS group. Neg, negative; Pos, positive.